BIO vs NDRA · rev $2.58B vs P/E 0.0, $2.6M cap
BIO (BIO) versus ENDRA Life Sciences Inc (NDRA) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
ENDRA Life Sciences Inc (NDRA) is a diagnostics & research company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
NDRA does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. NDRA currently screens at market cap $2.6M and trailing P/E 0.0.
Not investment advice. Open the BIO and NDRA stock pages for the full models.
Not investment advice.